T. Rowe Price Associates
KZR

T. Rowe Price Associates’s Kezar Life Sciences KZR Stock Holding History

T. Rowe Price Associates’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,360
Closed -$65K – 3035
2024
Q3 		$65K Hold
8,360
– – ﹤0.01% 2894
2024
Q2 		$51K Buy
8,360
+3,593
+75% +$27.3K ﹤0.01% 2852
2024
Q1 		$43K Buy
4,767
+132
+3% +$1.2K ﹤0.01% 2891
2023
Q4 		$44K Hold
4,635
– – ﹤0.01% 2828
2023
Q3 		$56K Buy
4,635
+1,870
+68% +$33.1K ﹤0.01% 2765
2023
Q2 		$68K Buy
2,765
+201
+8% +$5.23K ﹤0.01% 2765
2023
Q1 		$81K Buy
2,564
+98
+4% +$5.67K ﹤0.01% 2723
2022
Q4 		$174K Buy
2,466
+70
+3% +$5.19K ﹤0.01% 2575
2022
Q3 		$207K Buy
2,396
+862
+56% +$83.7K ﹤0.01% 2532
2022
Q2 		$127K Buy
+1,534
New +$135K ﹤0.01% 2713

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

T. Rowe Price Associates's KZR Position: Q4 2024 in Review

T. Rowe Price Associates sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 8,360 shares — an estimated $65K sold.

T. Rowe Price Associates first reported a position in KZR in Q2 2022 and held it in 10 quarters. The position peaked at $207K in Q3 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

  • T. Rowe Price Associates reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 8,360 Kezar Life Sciences shares in Q4 2024, an estimated $65K.
  • T. Rowe Price Associates first reported a position in Kezar Life Sciences in Q2 2022 and held it in 10 quarters.
  • T. Rowe Price Associates's Kezar Life Sciences position peaked at $207K in Q3 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.